Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Registrational; Therapeutic Use
- Acronyms ASCEND
- Sponsors Genentech; InterMune
- 12 Sep 2023 Results of meta analysis to compare FVC findings from the IPF patients enrolled in ATLAS to four studies (ASCEND, NPULSIS-1, INPULSIS-2 and INBUILD) presented in the Avalyn Pharma Media Release
- 30 Jun 2023 Results of pooled analysis (from studies ASCEND (NCT01366209), CAPACITY 004 (NCT00287716), CAPACITY 006 (NCT00287729), RECAP (NCT00662038), PASSPORT (NCT02699879), and SP-IPF (NCT02951429)published in the Advances in Therapy
- 19 Oct 2022 Results of post hoc analysis assessing the efficacy of pirfenidone on dyspnea in IPF, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians